News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Shin Nippon Biomedical Laboratories Agrees Licensing Nasal Drug Delivery Technology To Tokai Pharmaceuticals


8/14/2006 1:24:55 PM

ShinNippon Biomedical Laboratories' two subsidiaries, Translational Research Ltd.(TRL) and Bioactis Ltd. have signed general terms of agreement for the licensing and supplying of their patented nasal drug delivery technology in the field of endocrinology to Tokai Pharmaceuticals of Massachusetts, USA.

Read at JCN Newswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES